The CHMP's opinion is based on positive results from two late-stage studies on MRK's Welireg in two indications associated ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy ...

EU regulators recommend approval of Merck's drug Welireg for certain patients with VHL disease or advanced kidney cancer.

Merck & Co. said a key European regulatory committee has recommended conditional approval of its Welireg oral cancer drug in a pair of indications.

(RTTNews) - Drug major Merck & Co., Inc. (MRK) announced Friday that its WELIREG (belzutifan) has received positive opinion from the European Medicines Agency's Committee for Medicinal Products ...

Merck MRK announced that EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended granting conditional approval to its oral HIF-2α inhibitor, Welireg (belzutifan), for use ...

Merck (NYSE:MRK) has received a positive recommendation from EU regulators for its drug Welireg as a treatment for certain patients with von Hippel-Lindau disease, or VHL, and advanced kidney cancer.

Merck & Co. said a key European regulatory committee has recommended conditional approval of its Welireg oral cancer drug in a pair of indications. Merck on Friday said the recommendations from ...